Biosimilars
As the United States enters the world of generic biologic drugs, managing the clinical risks will be key for developers.
By Michael D. Christel
 

Intellectual Property and Patents
With the pharmaceutical patent cliff in full view, drugmakers are turning to a variety of approaches to sustain portfolios or add new intellectual property.
By Michael D. Christel

R&D Hotspots: Eastern Europe
Demand for increased investment in pharmaceutical innovation is growing louder in Russia and other Eastern European nations, but continued clinical development barriers could bog down efforts.
By Ed Silverman

Editor's Page
As the exploration and understanding of the genetic code continues, companies and the courts will be locked in struggles to define what can and cannot be patented.
By Christiane Truelove

R&D Business
Abbott Laboratories plans to split into two publicly traded companies next year.
By Colette Pilkus

Drugs in Development
Merck KGaA and Ono Pharmaceutical Co. enter agreements in multiple sclerosis and cancer.
By Colette Pilkus

Filed for Approval
Vivus Inc. resubmits new drug application for its experimental obesity drug Qnexa.
By Colette Pilkus

Q&A: Biobetters ripe with risk, reward
Andrea Weir, Ph.D., senior scientific advisor for Charles River Laboratories, talks with R&D Directions about the potential rewards and roadblocks of developing biobetter medicines.
By Michael D. Christel

Q&A: Patent expert on IP strategies, U.S. reform
Longtime intellectual property agent D’Vorah Graeser, Ph.D., discusses the benefits and challenges of the recent U.S. patent reform for life sciences companies.
By Michael D. Christel